AzTrials
AzTrials

DyspareuniaNCT04234555

What is the Nature of Pelvic Floor Muscle Involvement in Dyspareunia?

An observational study of Dyspareunia, run by University of Ottawa at 1 site in Canada.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Dyspareunia, or pain experienced by women during penetrative sexual activities, affects the psychological and sexual health of more than one in five Canadian women [1], yet its pathophysiology is poorly understood [2-4] and evidence for management approaches is limited.[5] It is thought that pelvic floor muscle (PFM)… Read more about this study

Who is it for?
Ages 18 to 45 years, women onlyHealthy volunteers can take part
Conditions the study is for
Dyspareunia
What is being tested?
Corticomotor excitability to the pelvic floor muscles, Pelvic floor muscle response to pressure applied at the vulvar vestibule and Pressure pain threshold (PPS)
Type of treatment
Pill or oral medicine
How many people
85 participants
Where
1 siteCanada
Study dates
2 Feb 2021to 20 Mar 2023
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 45 years
  • Women only
  • Healthy volunteers accepted
  • Adult

Study population: Females with PVD alone or PVD+ VAG will be recruited at the vulvar pain clinic at The Ottawa Hospital and from local physiotherapy clinics that cater to females with pelvic floor dysfunction. Control participants will be recruited from the local community through advertisements, word of mouth and social media.

Who may be able to join

  • Premenopausal women over the age of 18
  • Biologically born female
  • Signs and symptoms consistent with Provoked Vestibulodynia (PVD) alone or PVD+ Vaginismus (VAG) (i.e. evidence of a vaginal muscle spasm in response to palpation) or no history of pain during sexual activities or tampon insertion to serve as a comparison group
  • Not currently pregnant, or pregnant in the past six months.

Who cannot join

  • Neurological condition such as stroke, multiple sclerosis, spinal cord injury, epilepsy, or history of epilepsy in the family, etc
  • Metal implants (cochlear, pacemaker, etc.)
  • Tendency to faint
  • in Peri- or post-menopause
  • express high levels of anxiety about the assessment protocol

Trial locations and contacts

1 site in 1 country.

Canada1 site
  • Flavia Antonio

    Ottawa, Ontario, K1N 6N5

Other trials in Canada

About this study

Dyspareunia, or pain experienced by women during penetrative sexual activities, affects the psychological and sexual health of more than one in five Canadian women [1], yet its pathophysiology is poorly understood [2-4] and evidence for management approaches is limited.[5] It is thought that pelvic floor muscle (PFM) dysfunction is implicated in many forms of dyspareunia, while the nature and aetiology of this involvement remain largely unknown. The goal of this study is to understand if and how PFM dysfunction contributes to the pain experienced by women with provoked vestibulodynia (PVD), the most common cause of dyspareunia. This goal will be achieved through implementing an innovative and comprehensive approach to measuring the neuromuscular function of the PFMs. Understanding the pathophysiology of PVD is essential to the development of effective interventions to improve the health and quality of life of the many Canadian women who suffer from dyspareunia.

Read the detailed description

Despite its high prevalence, little is known about the aetiology of dyspareunia. Dyspareunia is often sub-classified by the location (generalized vs a specific region) and by the stimulus that induces pain (provoked vs spontaneous). As such, PVD is characterized by severe sharp and/or burning pain felt at the entrance to the vagina (i.e. the vulvar vestibule) when pressure is applied to this area (i.e. provoked). [2] PVD is considered to be the most common cause of dyspareunia in pre-menopausal women, with a prevalence of about 12% of women, [1] while it remains underreported due to stigma embarrassment and shame. [6] Among women who seek intervention for PVD, involuntary PFM activation is thought to play a significant role in the onset and/or maintenance of pain. [7-15] Indeed, PVD is sometimes accompanied by intense, involuntary contraction of the PFMs [3], termed vaginismus (VAG). Yet it is not known whether PVD and VAG are distinct entities, or whether VAG exists along some continuum of PVD severity; [8,16] a matter of much debate in the literature.[17,19]

There is evidence to suggest that PFM dysfunction is a feature of PVD even in the absence of VAG.[7-15,20] When assessed through intravaginal palpation, women with PVD (without VAG) present with higher PFM tone (i.e., greater resistance to a passive manual stretch of the PFMs), difficulty relaxing their PFMs following a contraction, and lower PFM strength when compared to asymptomatic women.[7-9] Yet strength and tone graded by palpation are subjective, and studies were performed without assessor blinding. Some of these palpation findings have been corroborated using electromyography (EMG), including higher than normal tonic PFM activation,[14,21,22] poor ability to achieve a PFM contraction [10], impaired ability to relax the PFMs after activation [4], and/or poor ability to sustain a consistent activation level on voluntary PFM contraction,[10,15,23] yet the latter findings have been refuted by others.[9,20,24-26] While this more objective evidence exists, studies on PFM involvement in PVD using EMG have been small (n<12), have carried high risk of bias, [27] and authors have often failed to report whether women with PVD had concurrent VAG, perpetuating the lack of clarity around diagnosis.

Indeed, it is often difficult to determine on clinical examination whether or not VAG is present in women with PVD [3] and the new Diagnostic and Statistical Manual of Mental Disorders (DSM-5) omits any distinction between PVD and VAG, referring to both as genito pelvic pain penetration disorder (GPPPD17,21). Yet PFM involvement in PVD that is accompanied by VAG (PVD+VAG) may be distinct from PFM dysfunction in PVD with no concurrent VAG. [4,27-31] While trying to understand the nature of PFM involvement in PVD, it remains prudent to evaluate the PFMs while distinguishing between those with PVD+VAG and those with PVD alone.[19] This study will contribute to our knowledge of the nature of PFM involvement in PVD, and will inform on differences in PFM involvement between those with PVD alone and those with PVD+VAG.

Objectives and hypotheses: The overall goal of this project is to determine whether alterations in tonic, voluntary, reflex or behavioural responses of the superficial and/or the deep layer of the (PFMs) are implicated in PVD and/or PVD+VAG. There are four main aims with associated hypotheses:

Aim 1: To measure and compare pressure pain threshold (PPT), Temporal Summation (TS) at the vulvar vestibule, pain reported during the tampon test, and sexual function.

Hypothesis 1 (a): Compared to pain-free controls, women with PVD and PVD+VAG will demonstrate (a) greater self-reported pain during the tampon test. (b) lower PPT, (c) higher TS, and (d) lower sexual function.

Aim 2: To measure corticomotor excitability of projections to the PFMs through motor evoked potentials (MEPs) and cortically mediated silent periods (cSPs).

Hypothesis 2(a) Compared to pain-free controls, women with PVD and PVD+VAG will have larger MEPs and shorter cSPs in the bulbocavernosus, pubovisceral, and external anal sphincter muscles in response to transcranial magnetic stimulation (TMS) of the cortical area corresponding to the PFMs.

Hypothesis 2(b) Differences will be evident between women with PVD and PVD+VAG.

Aim 3: To measure the amplitude and timing of EMG responses to pressure applied to the vulvar vestibule and the posterior thigh Hypothesis 3 (a): Compared to pain-free controls, women with PVD and PVD+VAG will have higher incidences of anticipatory responses (ie. responses recorded before pressure is applied) recorded from the PFMs (bulbocavernosus, pubovisceral, external anal sphincter) and remote (uppper trapezius, hip adductor) muscles when standardized pressure stimuli are applied to the posterior vaginal fourchette regardless of the intensity of the pressure (low vs moderate).

Hypothesis 3 (b): Compared to pain-free controls, women with PVD and PVD+VAG will have higher muscle activation amplitude responses in the PFMs (bulbocavernosus, pubovisceral, external anal sphincter) and in more remote muscles (trapezius and hip adductor muscles) after standardized pressure stimuli (both low and moderate) are applied to the posterior vaginal fourchette.

Hypothesis 3 (c): Compared to pain-free controls, women with PVD and PVD+VAG will demonstrate larger responses in the PFMs (bulbocavernosus, pubovisceral, external anal sphincter) and in more remote muscles (trapezius or hip adductors) in response to pressure that is applied to the posterior thigh.

Aim 4: To measure the amplitude of PFM activation at rest (tonic), during maximum effort voluntary contraction of the PFMs and during a straining (Valsalva) maneuver Hypothesis 4: Compared to pain-free controls, women with PVD and PVD+VAG will demonstrate (a) higher tonic PFM activation, (b) more PFM activation during straining efforts (dyssynergia) and (c) lower PFM activation on maximum voluntary contraction.

Novelty and Contributions to the advancement of knowledge: Through this study, a comprehensive picture of neuromuscular impairments in the PFMs that are associated with PVD will be generated. Through Aim 1 it is expected to find in women with PVD and PVD+VAG, greater self reported pain during tampon test, lower pressure pain threshold, higher temporal summation and lower sexual function comparing with the control group. No study has investigated corticomotor excitability of projections to the PFMs through TMS. Through Aim 2 differences in corticomotor excitability to the PFMs, evidenced through higher amplitude MEPs and shorter duration cSPs are expected to be found, between women with and without PVD as well as differences in the extent of enhanced corticomotor excitability to the PFMs between PVD and PVD+VAG. Also no study has evaluated whether differences seen in tonic or phasic responses of the PFMs between women with PVD and controls are present because of or in anticipation of pain. Studies by Van Lunsen \& Ramakers [32], Reissing et al. [8] and van der Velde \& Everaerd [33] suggest that the PFMs respond to generalized anxiety and in response to watching sexually threatening scenes. It is quite possible, and even probable, that anxiety or fear of pain may influence study outcomes [4,34]. Through Aim 3, the timing and magnitude of PFM activation will be evaluated to determine whether responses occur in anticipation of (i.e. before) and/or in response to pressure stimuli delivered at the vulvar vestibule. The hypotheses under Aims 2 and 3 have never before been tested and doing so will have a significant impact on our understanding of the pathophysiology of PVD. Through Aim 4, it we expect to corroborate previous findings in the literature: that women with PVD and PVD+VAG will demonstrate higher tonic PFM activation and PFM dyssynergia during straining - both being functionally related to increased corticomotor excitability.

If women with PVD+VAG exhibit higher corticomotor excitability than women with PVD alone, this finding will be a major step toward understanding PVD and PVD+VAG as separate conditions, and will set the stage for improved diagnoses and targeted treatments such as repetitive TMS35 and neurotropic medications.[36] Further, interventions that have shown some evidence for effectiveness [37] including stretching, [9,38,39] acupuncture, [40] Botox injection, [41,42] and cognitive behavioural therapy [39] may be enhanced by combining them with new interventions that focus on corticomotor inhibition. The impact of any new as well as existing interventions on corticomotor excitability can, in turn, be evaluated using the innovative yet accessible assessment approaches developed through this work.

For descriptive purposes, five on-line questionnaires will be applied to assess sexual function [43,44], pain [45] pain catastrophising [46], depression/anxiety [47,48], and central sensitization [49].

Assessment will be scheduled within the week following the start of women's last menstrual cycle to account for cyclic variations in motor and sensory thresholds [50] , and at a time that is convenient.

Conditions
Dyspareunia
Being tested
Corticomotor excitability to the pelvic floor muscles, Pelvic floor muscle response to pressure applied at the vulvar vestibule, Pressure pain threshold (PPS), Temporal summation of pain, Tonic, phasic and reflex activation of the pelvic floor muscles (PFMs)
Keywords
dyspareunia, electromyography, transcranial magnetic stimulation, pressure pain threshold, temporal summation, vaginismus, provoked vestibulodynia
Medical subject headings
Dyspareunia, Vaginismus

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Corticomotor excitability to the pelvic floor musclesDiagnostic test

    Transcranial magenetic stimulation will be used to probe the excitability of cortical projections to the pelvic floor muscles. The outcomes of interest will include motor evoked potential amplitude and silent period.

  • Pelvic floor muscle response to pressure applied at the vulvar vestibuleDiagnostic test

    Electromyography will be used to determine whether the pelvic floor muscles (PFMs) respond to pressure applied to the vulvar vestibule as anticipatory (i.e. PFMs are active before the pressure is applied) and as behavioural (i.e. PFMs are active after the pressure is applied) responses. The amplitude of the EMG responses will also be recorded.

  • Pressure pain threshold (PPS)Diagnostic test

    A custom vulvalgesiometer will be used to determine the mean pressure at which participants first report pain at the posterior vaginal fourchette.

  • Temporal summation of painDiagnostic test

    A custom vulvalgesiometer will be used to apply the same pressure (rated as 4/10 duiring PPS testing as described above) to the vulvar vestibule across 10 repetitions. The difference in pain rated on the tenth application and that rated on the first application will be the outcome.

  • Tonic, phasic and reflex activation of the pelvic floor muscles (PFMs)Diagnostic test

    Electromyography will be used to measure the mean smoothed, rectified activation amplitude across 1 second of complete rest, across three maximal effort PFM contractions, and across three attempts at a bearing down maneuver.

Study groups in NCT04234555
Study groupRoleWhat they receive
Provoked vestibulodynia (PVD)Provoked vestibulodynia (PVD) is characterized by severe sharp and/or burning pain felt at the entrance to the vagina (i.e. the vulvar vestibule) when pressure is applied to this area or during attempts at vaginal insertional activities (i.e. provoked).
Receives: Diagnostic Test: Corticomotor excitability to the pelvic floor muscles; Diagnostic Test: Pelvic floor muscle response to pressure applied at the vulvar vestibule; Diagnostic Test: Pressure pain threshold (PPS); Diagnostic Test: Temporal summation of pain; Diagnostic Test: Tonic, phasic and reflex activation of the pelvic floor muscles (PFMs)
Provoked vestibulodynia (PVD) + Vaginismus (VAG)PVD is sometimes accompanied by intense, involuntary contraction of the PFMs3, termed vaginismus (VAG).
Receives: Diagnostic Test: Corticomotor excitability to the pelvic floor muscles; Diagnostic Test: Pelvic floor muscle response to pressure applied at the vulvar vestibule; Diagnostic Test: Pressure pain threshold (PPS); Diagnostic Test: Temporal summation of pain; Diagnostic Test: Tonic, phasic and reflex activation of the pelvic floor muscles (PFMs)
ControlParticipants matched by age (within 2 years), parity (parous vs nulliparous) and use of oral contraceptive medications (yes vs no) to women in the PVD group, with no signs and symptoms of PVD.
Receives: Diagnostic Test: Corticomotor excitability to the pelvic floor muscles; Diagnostic Test: Pelvic floor muscle response to pressure applied at the vulvar vestibule; Diagnostic Test: Pressure pain threshold (PPS); Diagnostic Test: Temporal summation of pain; Diagnostic Test: Tonic, phasic and reflex activation of the pelvic floor muscles (PFMs)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Motor evoked potential (MEP) peak to peak amplitude (µV)

    Transcranial magnetic stimulation outcome (i.e. Motor evoked potential peak to peak amplitude - µV) will be determined for all participants and compared among groups.

    A Magstim® 200 system coupled with a double cone coil (96 mm loops, P/N 9902) [57] will be used to probe the corticospinal projections to PFMs. MEPs will be ensemble averaged to generate estimates of MEP peak to peak amplitude (µV).

    Measured: 1 day

  2. Cortical silent period duration (ms)

    Transcranial magnetic stimulation outcome (i.e. cortical silent period duration - ms) will be determined for all participants and compared among groups.

    A Magstim® 200 system coupled with a double cone coil (96 mm loops, P/N 9902) [57] will be used to probe the corticospinal projections to PFMs. MEP cortical silent period (cSP) will be measured from individual trials and then averaged.

    Measured: 1 day

  3. Anticipatory responses (ms)

    The proportion of women in each group who demonstrate anticipatory responses of the PFMs to impending pressure applied at the vulvar vestibule will be determined for each group. Participants will be deemed to have anticipatory responses if electromyographic signals recorded from the PFMs precede the application of pressure. A vulvalgesiometer [58] will be employed using a response-dependent methodology. [59,60] The vulvalgesiometer will be used to apply low (25 g) and moderate (232 g) pressures to the posterior vaginal fourchette or to the posterior thigh, the moderate value having been generated through the team's previous research. [9]

    Measured: 1 day

  4. Behavioural responses (µV)

    The proportion of women in each group who demonstrate behavioral responses of the PFMs to pressure applied at the vulvar vestibule will be determined for each group. Participants will be deemed to have behavioural if the activation of the PFMs (or other muscles) occurs after the pressure is applied. A vulvalgesiometer [58] will be employed using a response-dependent methodology. [59,60] The vulvalgesiometer will be used to apply low (25 g) and moderate (232 g) pressures to the posterior vaginal fourchette or to the posterior thigh, the moderate value having been generated through the team's previous research. [9]

    Measured: 1 day

  5. Tonic, phasic and reflex activation of the pelvic floor muscles

    Surface Electromyography (EMG) recorded using differential suction electrodes (DSEs, developed by Dr. McLean) [54-56] will be used to measure tonic, voluntary and reflex activation of the superficial and deep PFMs. Smoothed peak EMG amplitudes (µV) will be computed as outcomes while women keep their PFMs as relaxed as possible (tonic), contract as strongly as possible (phasic) and perform a straining maneuver (reflex activation).

    Measured: 1 day

Secondary outcomes (3)
  1. Tampon test

    Women will be instructed to insert and then remove the tampon and they will be instructed to record the degree of pain during the entire insertion/ removal experience on a 0-10 pain numeric rating scale, with 0 meaning no pain, and 10 meaning the worst possible pain.

    Measured: 1 day

  2. Pressure pain threshold (PPT)

    The pressure at which women report pain on pressure applied through a cotton swab to the region of the posterior vaginal fourchette.

    Pressure pain threshold (PPT) will be determined using a custom vulvalgesiometer. PPT will be defined as the average pressure at which women first report pain when the cotton swab tip of the vulvalgesiometer is applied at 6 o' clock of the vaginal introitus [51].

    Measured: 1 day

  3. Temporal summation (TS) of pain

    The difference in pain rating (scale 1-10) between the tenth and first application of a pressure applied to the posterior vaginal fourchette through a custom vulvalgesiometer.

    The PPT determined at the 6-o-clock position, will be applied ten times at a rate of approximately one per second at the 6 o'clock location on the vestibule. Participants will rate their pain level on the initial and final application of this pressure using a Numeric Rating Scale (0-10). TS will be defined as the difference in pain rating between the final and first application of the pressure [52,53]

    Measured: 1 day

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted21 Jan 2020
  2. Study start2 Feb 2021
  3. Primary completion15 Jan 2023
  4. Study completion20 Mar 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Cross-sectional
Enrolment
85 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04234555
Sponsor's protocol ID
H-11-18-1183
Status last verified
Mar 2023
First submitted
10 Jan 2020
Last updated
4 Apr 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: Spreadsheets will be provided by email upon request and based on the planned use of the data.

Publications

  • Harlow BL, Stewart EG. A population-based assessment of chronic unexplained vulvar pain: have we underestimated the prevalence of vulvodynia? J Am Med Womens Assoc (1972). 2003 Spring;58(2):82-8.

    PubMed 12744420
  • Bergeron S, Binik YM, Khalife S, Pagidas K, Glazer HI. Vulvar vestibulitis syndrome: reliability of diagnosis and evaluation of current diagnostic criteria. Obstet Gynecol. 2001 Jul;98(1):45-51. doi: 10.1016/s0029-7844(01)01389-8.

    PubMed 11430955
  • de Kruiff ME, ter Kuile MM, Weijenborg PT, van Lankveld JJ. Vaginismus and dyspareunia: is there a difference in clinical presentation? J Psychosom Obstet Gynaecol. 2000 Sep;21(3):149-55. doi: 10.3109/01674820009075622.

    PubMed 11076336
  • Lahaie MA, Amsel R, Khalife S, Boyer S, Faaborg-Andersen M, Binik YM. Can Fear, Pain, and Muscle Tension Discriminate Vaginismus from Dyspareunia/Provoked Vestibulodynia? Implications for the New DSM-5 Diagnosis of Genito-Pelvic Pain/Penetration Disorder. Arch Sex Behav. 2015 Aug;44(6):1537-50. doi: 10.1007/s10508-014-0430-z. Epub 2014 Nov 15.

    PubMed 25398588
  • Andrews JC. Vulvodynia interventions--systematic review and evidence grading. Obstet Gynecol Surv. 2011 May;66(5):299-315. doi: 10.1097/OGX.0b013e3182277fb7.

    PubMed 21794194
  • Donaldson RL, Meana M. Early dyspareunia experience in young women: confusion, consequences, and help-seeking barriers. J Sex Med. 2011 Mar;8(3):814-23. doi: 10.1111/j.1743-6109.2010.02150.x. Epub 2010 Dec 8.

    PubMed 21143423
  • Reissing ED, Brown C, Lord MJ, Binik YM, Khalife S. Pelvic floor muscle functioning in women with vulvar vestibulitis syndrome. J Psychosom Obstet Gynaecol. 2005 Jun;26(2):107-13. doi: 10.1080/01443610400023106.

    PubMed 16050536
  • Reissing ED, Binik YM, Khalife S, Cohen D, Amsel R. Vaginal spasm, pain, and behavior: an empirical investigation of the diagnosis of vaginismus. Arch Sex Behav. 2004 Feb;33(1):5-17. doi: 10.1023/B:ASEB.0000007458.32852.c8.

    PubMed 14739686
  • Gentilcore-Saulnier E, McLean L, Goldfinger C, Pukall CF, Chamberlain S. Pelvic floor muscle assessment outcomes in women with and without provoked vestibulodynia and the impact of a physical therapy program. J Sex Med. 2010 Feb;7(2 Pt 2):1003-22. doi: 10.1111/j.1743-6109.2009.01642.x. Epub 2010 Jan 6.

    PubMed 20059663
  • Glazer HI, Rodke G, Swencionis C, Hertz R, Young AW. Treatment of vulvar vestibulitis syndrome with electromyographic biofeedback of pelvic floor musculature. J Reprod Med. 1995 Apr;40(4):283-90.

    PubMed 7623358
  • Morin M, Bergeron S, Khalife S, Mayrand MH, Binik YM. Morphometry of the pelvic floor muscles in women with and without provoked vestibulodynia using 4D ultrasound. J Sex Med. 2014 Mar;11(3):776-85. doi: 10.1111/jsm.12367. Epub 2013 Nov 6.

    PubMed 24344835
  • 12. Morin M, Bergeron S, Khalife S, Binik I, Ouellet S. Dynamometric assessment of the pelvic floor muscle function in women with and without provoked vestibulodynia. Int Urogynecol J 2010: 21: S336-S37.

  • McKay E, Kaufman RH, Doctor U, Berkova Z, Glazer H, Redko V. Treating vulvar vestibulitis with electromyographic biofeedback of pelvic floor musculature. J Reprod Med. 2001 Apr;46(4):337-42.

    PubMed 11354833
  • Frasson E, Graziottin A, Priori A, Dall'ora E, Didone G, Garbin EL, Vicentini S, Bertolasi L. Central nervous system abnormalities in vaginismus. Clin Neurophysiol. 2009 Jan;120(1):117-22. doi: 10.1016/j.clinph.2008.10.156. Epub 2008 Dec 13.

    PubMed 19071060
  • White G, Jantos M, Glazer H. Establishing the diagnosis of vulvar vestibulitis. J Reprod Med. 1997 Mar;42(3):157-60.

    PubMed 9109083

Questions about this trial

What is this clinical trial studying?

An observational study of Dyspareunia, run by University of Ottawa at 1 site in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 4 Apr 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Motor evoked potential (MEP) peak to peak amplitude (µV) (time frame: 1 day). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04234555, which also lists 60 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Apr 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in